121 related articles for article (PubMed ID: 8728209)
1. Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD.
Nevalainen PI; Lahtela JT; Mustonen J; Pasternack A
Perit Dial Int; 1996; 16 Suppl 1():S288-91. PubMed ID: 8728209
[TBL] [Abstract][Full Text] [Related]
2. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients.
Nevalainen P; Lahtela JT; Mustonen J; Pasternack A
Nephrol Dial Transplant; 1997 Jan; 12(1):145-50. PubMed ID: 9027790
[TBL] [Abstract][Full Text] [Related]
3. The effect of insulin delivery route on lipoproteins in type I diabetic patients on CAPD.
Nevalainen PI; Lahtela JT; Mustonen J; Taskinen MR; Pasternack A
Perit Dial Int; 1999; 19(2):148-53. PubMed ID: 10357186
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment.
Scarpioni L; Ballocchi S; Scarpioni R; Cristinelli L
Perit Dial Int; 1996; 16 Suppl 1():S275-8. PubMed ID: 8728206
[No Abstract] [Full Text] [Related]
5. Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type I diabetic patients on continuous ambulatory peritoneal dialysis treatment.
Lahtela JT; Mustonen J; Pasternack A
Clin Sci (Lond); 1995 Apr; 88(4):427-32. PubMed ID: 7789044
[TBL] [Abstract][Full Text] [Related]
6. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration.
Scarpioni L; Ballocchi S; Castelli A; Scarpioni R
Perit Dial Int; 1994; 14(2):127-31. PubMed ID: 8043664
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials.
Almalki MH; Altuwaijri MA; Almehthel MS; Sirrs SM; Singh RS
Clin Invest Med; 2012 Jun; 35(3):E132-43. PubMed ID: 22673316
[TBL] [Abstract][Full Text] [Related]
8. Continuous ambulatory peritoneal dialysis in diabetes mellitus. The risks and benefits of intraperitoneal insulin.
Madden MA; Zimmerman SW; Simpson DP
Am J Nephrol; 1982; 2(3):133-9. PubMed ID: 6758585
[TBL] [Abstract][Full Text] [Related]
9. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration.
Quellhorst E
J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S92-6. PubMed ID: 11792768
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal insulin reduces plasma leptin concentration in diabetic patients on CAPD.
Nevalainen PI; Lahtela JT; Mustonen J; Pasternack A
Perit Dial Int; 2000; 20(1):27-32. PubMed ID: 10716580
[TBL] [Abstract][Full Text] [Related]
11. Decreasing insulin requirements in CAPD patients given intraperitoneal insulin.
Grefberg N; Danielson BG; Berne C
J Diabet Complications; 1987; 1(1):16-9. PubMed ID: 2968990
[TBL] [Abstract][Full Text] [Related]
12. Improvement of glycemic control by CAPD with intraperitoneal insulin in a child with IDDM and ESRD.
Flynn JT; Kershaw DB; Sedman AB; Smoyer WE; Bunchman TE
Adv Perit Dial; 1998; 14():265-8. PubMed ID: 10649738
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal insulin in continuous ambulatory peritoneal dialysis (CAPD): clinical aspects.
Triolo G; Carta Q; Salomone M; Dani F; Passarino G; Boggio Bertinet D; Segoloni GP; Vercellone A
Life Support Syst; 1983; 1 Suppl 1():454-6. PubMed ID: 6400733
[No Abstract] [Full Text] [Related]
14. Continuous ambulatory peritoneal dialysis in diabetic patients with end-stage renal disease: experience with intraperitoneal insulin therapy.
Chen HC; Lai YH; Tsai CY; Shin SJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Feb; 7(2):56-61. PubMed ID: 2005672
[TBL] [Abstract][Full Text] [Related]
15. Administration of insulin by continuous ambulatory peritoneal dialysis.
Chan E; Montgomery PA
Pharmacotherapy; 1993; 13(5):455-60. PubMed ID: 8247911
[TBL] [Abstract][Full Text] [Related]
16. Blood glucose and cholesterol control improved by continuous ambulatory peritoneal dialysis in patients with end-stage renal disease and diabetes mellitus.
Wikdahl AM; Granbom L; Sörensen JG; Stegmayr BG
Perit Dial Int; 1993; 13 Suppl 2():S239-41. PubMed ID: 8399577
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review.
Tzamaloukas AH; Oreopoulos DG
Adv Perit Dial; 1991; 7():81-5. PubMed ID: 1680463
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of the administration of intraperitoneal insulin in diabetic patients undergoing continuous ambulatory peritoneal dialysis].
Coronel Díaz F; Naranjo Gómez P; Serrano Heranz R; Cruceyra Ventín A; Prats Sánchez D
Med Clin (Barc); 1984 May; 82(20):881-4. PubMed ID: 6379332
[No Abstract] [Full Text] [Related]
19. Effect of beta-blocker therapy on serum lipoprotein profiles in patients on renal dialysis and in diabetic nephropathy.
Kontessis PS; Jayathissa SA; Walker JD; Mattock MB; Williams DG; Viberti GC
Diabetes Res; 1993; 23(3):93-104. PubMed ID: 7712687
[TBL] [Abstract][Full Text] [Related]
20. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin.
Nevalainen PI; Kallio T; Lahtela JT; Mustonen J; Pasternack AI
Perit Dial Int; 2000; 20(6):637-42. PubMed ID: 11216552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
